EVs released from treatment-resistant variants of HER2+ BC contained high levels of the immunosuppressive cytokine TGF-β1 and increased PD-L1, and were resistant to HER2 antibody trastuzumab-mediated cytotoxicity [73]. The gene discussed is ERBB2; the disease is breast cancer.